Kornimate/medical-research-clean huggingface dataset:
guided internet-based trauma-focused cbt programme for post-traumatic stress disorder 'spring'

Conditions: Posttraumatic Stress Disorder

Summary: the main aim of the study is to evaluate the efficacy of the lithuanian version of the internet-based guided self-help programme (spring) in reducing icd-11 ptsd symptoms.

spring is an online guided self-help programme for the reduction of posttraumatic stress disorder symptoms. it is based on the principles of trauma-focused cognitive behavioral therapy and consists of 8 steps covering psychoeducation, grounding techniques, management of anxiety, behavioral activation, imaginal exposure, cognitive restructuring, in vivo exposure, and prevention of relapse. the user of the programme also receives up to 3 hours of therapist guidance. originally spring was developed by the research team at cardiff university. in the current study, the most recent second version of the spring programme adapted to the lithuanian population will be used. the main aim of the study is to evaluate the efficacy of the lithuanian version of the spring programme in reducing icd-11 posttraumatic stress disorder symptoms.

Eligibility criteria:
inclusion criteria: * aged 18 years or over * ability to read and write fluently in lithuanian * have regular access to a device with an internet connection to use the programme * provide informed consent for participation * experience ptsd symptoms followed by a non-prolonged and non-repetitive traumatic experience as measured by the iti exclusion criteria: * regularly seeing a therapist or counsellor for mental health issues * change in psychotropic medication in the last month * cptsd diagnosis * psychosis * severe suicide risk * substance dependence * experiencing ongoing threat

Keywords: trauma posttraumatic stress treatment cognitive behavior therapy internet-based intervention
reducing preterm births in underserved pregnant women

Conditions: Preterm Birth; Low Birth Weight <2500 Grams; Verylow Birthweight <1500 Grams

Summary: timely screening and management of modifiable conditions can reduce preterm births, yet providing effective prenatal risk management systems to meet the unique needs of medically underserved populations is complex. if the proposed system proves to be effective in reducing preterm births it can improve maternal and child quality of life as well as reduce the economic burden of preterm births in the u.s.

the primary aim of this proposal is to test the efficacy of a clinic-based, computer-assisted intervention system to significantly reduce preterm births in high-risk populations. this system will: (1) assess a pregnant woman's unique risks in six modifiable areas associated with increased risks of preterm birth including smoking cessation, poor nutrition, domestic violence, maternal depression and stress, urinary and reproductive tract infections and substance use; (2) provide her with tailored advice and action planning tools on reducing her risks; (3) provide her certified nurse midwife or physician with information related to her assessed risks and counseling suggestions tailored for her needs, and \[(4) promote effective referrals to, and successful linkages with community-based support organizations.\] because preterm birth rates are much higher for underserved african american women, we are proposing to focus the intervention with this population.

Eligibility criteria:
inclusion criteria: study inclusion criteria include: 1. age 16-48 years, 2. 1st trimester of pregnancy, 3. race/ethnicity (non-hispanic black, or english-speaking hispanic black), and 4) a self-reported completion of grade 6 or higher. exclusion criteria: exclusion criteria include: 1. a medical condition or risk to the pregnancy that the physician or nurse midwife determines serious and a reason for exclusion, and 2. a literacy level of \< grade 6. no prior experience using a computer is needed. -

Keywords: computer-based behavioral support
nicotine as an adjuvant analgesic for third molar surgery

Conditions: Dental Crowding

Summary: third molar surgery is complicated by pain and swelling for several days after surgery. non-steroidal antiinflammatory drugs have been useful in combination with opioids for treatment. nicotine has antiinflammatory and pain relieving properties. we will use nicotine or placebo as a nasal spray before surgery to determine whether nicotine affects pain or inflammation.

this is a randomized double blind cross-over study. in each of two sittings, the third molars on one side of the mouth are removed. in one sitting the subject will receive a nicotine nasal spray (3mg) and in the other placebo. vas and narcotic utilization will be compared within patients.

Eligibility criteria:
inclusion criteria: * over 18 * 4 molars to be removed exclusion criteria: * pregnant * lactating * chronic pain * narcotic use * asthma * ex-smokers

Keywords: third molar pain
the clinical and biomechanical research of the new arthroscopic technique for the treatment of high-grade dislocation of the acromioclavicular joint

Conditions: Dislocation of the Acromioclavicular Joint

Summary: acromioclavicular joint dislocation is a common disease in shoulder surgery, which mostly occurs in young and middle-aged patients. severe acromioclavicular joint dislocations of rockwood type iv, v, and vi require surgical treatment. among them, the common clinical type iv and type v severe acromioclavicular joint dislocations are often treated with autologous/allogenous tendon transplantation and coracoclavicular ligament reconstruction under shoulder arthroscopy. although this minimally invasive surgical method has certain advantages over incision surgery, due to factors such as poor healing after tendon transplantation and failure of coracoclavicular fixation, the recurrence rate of postoperative dislocation is still as high as 30%, which seriously affects the prognosis of patients. therefore, we proposed a new surgical technique of minimally invasive shoulder arthroscopic coracoclavicular suspension fixation and coracoclavicular ligament residual reconstruction, which aims to strengthen the fixation strength of the coracoclavicular space, promote the healing of the coracoclavicular ligament, and reduce the recurrence rate of postoperative dislocation. to improve postoperative shoulder joint function of patients. this project intends to use non-randomized controlled clinical research and biomechanical research to compare traditional surgical techniques with new microscopic techniques in terms of surgical efficacy, postoperative complications, and internal plant fixation strength to establish the therapeutic advantages of the new technology. its application and promotion provide important clinical evidence to improve the treatment of severe acromioclavicular joint dislocation in the field of shoulder surgery.


Eligibility criteria:
inclusion criteria: * consecutive cases of coracoclavicular ligament reconstruction surgery usingtightrope device with allograft augmentation and shoulder arthroscopic reconstruction of coracoclavicular ligament with autologous/allogeneic tendon transplantation. * injury type rockwood type iv and v type severe acromioclavicular joint dislocation * the time from injury to operation is less than 3 weeks exclusion criteria: * combined with neurovascular injury * previous history of ipsilateral shoulder surgery * the patient refused to sign the informed consent and participate in the trial
effect of trimetazidine during the primary pci on cardiac function in patients with st-elevation myocardial infarction

Conditions: Cardiovascular Diseases

Summary: giving preoperative loading dose of 60mg of trimetazidine can safely and effectively reduce the pci-related myocardial damage for the patients undergoing selective pci. but the effect of trimetazidine during the primary pci on cardiac function in patients with st-elevation myocardial infarction is not sure. this study aim to study the effect of trimetazidine during the primary pci on cardiac function in patients with st-elevation myocardial infarction.

investigators will enroll 240 patients with stemi who were admitted to the chinese pla general hospital between januay 2017 and august 2017. stemi was defined as typical chest pain lasting 30 min within the previous 12 h, a clear st-segment elevation of n0.1 mv in ≥2 contiguous electrocardiographic leads, and elevated blood levels of troponin t. we randomly assign eligible patients in a 1:1 ratio to either 60mg of trimetazidine or oral placebo befor pci. trimetazidine group will accept 20mg of trimetazidine for 12 months after pci and active comparator will be given placebo for 12 months after pci. primary end point of the study was the area of viable myocardium coming from mr delayed enhancement scan and main cardiovascular events concluding recurrent myocardial infarction, cardiac death, recurrent angina, acute heart failure. secondary end point of the study was the change of lvef. all adverse clinical events as well as study end points were monitored and adjudicated by the independent event committee. each patient was contacted in every week after administration of the contrast, investigated main cardiovascular events (myocardial infarction,acute heart failure and death), and record any adverse events.

Eligibility criteria:
inclusion criteria: * stemi patients: typical chest pain lasting 30 min within the previous 12 h, a clear st-segment elevation of n0.1 mv in ≥2 contiguous electrocardiographic leads, and elevated blood levels of troponin t * patients were scheduled to undergo diagnostic cardiac angiography or percutaneous coronary interventions exclusion criteria: * the combined use of trimetazidine contraindications; * had cardiogenic shock, * had a history of myocardial infarction, stent thrombosis, or renal insufficiency; * had previously undergone coronary artery bypass surgery.

Keywords: trimetazidine st-segment elevation myocardial reperfusion injury percutaneous coronary intervention
study of ffi-1010 in pediatric kidney disease

Conditions: Children Under 18 Years Old With Kidney Disease

Summary: the purpose of this study is revealing that the ratio of creatinine clearance (ccr) to inulin clearance (cin) measuring at the same time is more than 1.2.


Eligibility criteria:
inclusion criteria: * kidney disease patients requiring exact evaluation of kidney function * egfr: \>=30 and \<=89 ml/min/1.73m\^2 exclusion criteria: * edema on the day before start of study treatment * oliguria on the day before start of study treatment * dehydration on the day before start of study treatment * infection or inflammatory disease before administration * history of epilepsy or organic brain disorder * history of, clinically significant cardiac, hematologic, hepatic and pancreatic disease
intravenous iron injection in cancer patients with anemia

Conditions: Cancer Anaemia

Summary: * multifactorial pathogenesis is involved in anemia of cancer patients and defining the causes of anemia is not always simple. * currently, treatment options available for anemia in cancer patients include red blood cell (rbc) transfusion, erythropoietin stimulating agent (esa), and iron supplementation, accompanying considerable pros and cons for each treatment. * previous studies have demonstrated benefit when treating with iv iron in combination with esa and, more recently, evidence is emerging to suggest a role for iv iron alone. * in this study, investigator will assess the efficacy of intravenous iron for the treatment of anemia in cancer patients. * improvement of anemia and the improvement of quality of life compared to conservative treatment of intravenous iron

this study is a comparative clinical trial of prospective, multicenter, randomized trials to evaluate the efficacy of intravenous iron (ferinject®) in cancer patients with anemia. changes in hemoglobin in the treated and conservative treatment groups with a single intravenous ferrinject® in patients with anemia by chemotherapy are identified. 1. clinical drug ferinject injection for patients undergoing chemotherapy, ferinject 1000mg will be injected within 24 hours or 24 hours after day 1 of the next chemotherapy cycle. patients using targeted therapies can be dosed at any time after recognizing hb 8.0-10.5g / dl and injecting 1000 mg of ferinject. * the administration of ferinject is a single dose, no re-administration. if chemotherapy is not performed, it can be administered at any time if the selection and exclusion criteria are met. * the administration period for ferinject should be administered within 24 hours or 24 hours after the day 1 of the chemotherapy cycle based on the results of phase 2 studies 2. remedies within the period of sample collection of visits 2 to 4 after study enrollment, if the physician determines that treatment for clinically meaningful anemia is necessary, treatment for anemia other than ferinjects will be followed. treatment for anemia will include remedies such as iron (oral or intravenous), hematopoietic accelerators, and blood transfusions, and will be determined by researchers at each institution to provide optimal treatment for patients. at the time this treatment is administered, the subject will be dropped from the clinical trial.

Eligibility criteria:
inclusion criteria: the subject should be diagnosed with solid cancer or lymphoma. hemoglobin level of test subject should be in the range of 8.0-10.5g / dl, or he / she has experienced hemoglobin reduction of 2g / dl or more during chemotherapy. exclusion criteria: the patients have a history of iron (oral or intravenous), hematopoietic stimulating agents (esa), and dialysis within 4 weeks of study enrollment. there is evidence that the patient's disease is a bone marrow invasion. there is a hypersensitivity reaction to ferinject or the components of ferinject.
probiotics in elderly patients with medical conditions

Conditions: Aging; Constipation; Multi-Core Disease

Summary: study of efficacy of probiotic in older patients with multiple co-morbidites and constipation

background and aims: probiotics are known to have a beneficial effect on the management of constipation. thus, the current study objective was to evaluate the impact of a microbial cell preparation (mcp) (hexbio®; comprising bifidobacterium and lactobacillus strains) on stool frequency, consistency, and constipation-related symptoms in elderly patients with multiple chronic medical conditions.

Eligibility criteria:
inclusion criteria: -clinical diagnosis of constipation exclusion criteria: * parkinson's disease, * spinal cord lesions * post radiation strictures * on calcium supplements of greater than 1,500 mg per day * immune-deficiency * critical illness

Keywords: microbial cell preparation hexbio® probiotics elderly chronic medical conditions constipation,
national registry of cardiovascular surgery in argentine

Conditions: Cardiovascular Diseases; Surgery

Summary: the national registry of cardiovascular surgery in argentina is a registry of patients undergoing cardiovascular surgery that involves the entire country with the ultimate aim of determining the results of said surgery throughout the country.

it is an observational registry with selective inclusion of patients who undergo certain cardiovascular surgeries, where the pre-surgical status will be analyzed, the determinants during surgery and the postoperative evolution of said patients will be evaluated

Eligibility criteria:
iinclusion criteria: over 18 years myocardial revascularization surgery valvular surgeries ascending aortic surgery type a aortic dissection surgery combined surgery exclusion criteria: cardiovascular surgery for congenital pathologies peripheral vascular surgery cardiovascular surgery secondary to trauma thoracic and abdominal aorta pathology other surgeries
primary angioplasty for acute myocardial infarction in patients with symptom duration above 12 hours

Conditions: Acute Myocardial Infarction

Summary: background: acute balloon angioplasty is beneficial in patients with acute myocardial infarction. however, presently this treatment is not offered to patients with symptom duration above 12 hours. hypothesis: acute balloon angioplasty for myocardial infarction is beneficial despite symptom duration above 12 hours. methods: in 60 patients with myocardial infarction and symptom duration above 12 hours, the proportion of non-perfused myocardium before acute angioplasty and 1 month after angioplasty is compared to evaluate if myocardial tissue can be saved by acute angioplasty despite long symptom duration.

methods: on arrival at our angioplasty laboratory, patients are informed about the study. if they accept to participate, we infuse 600 mbq of sestamibi i.v. this binds in a first passage fashion without later redistribution to perfused myocardium. non-perfused myocardium does not bind sestamibi. primary angioplasty with stent and abciximab is then performed followed by myocardial scintigraphy to illustrate the non-perfused myocardial area that was at risk of infarction before the coronary artery was opened. echocardiography is also performed. at 1 month, myocardial scintigraphy is repeated to evaluate infarct size. the difference between the myocardial area at risk of infarction before angioplasty and the myocardial infarct size 1 month later is defined as "salvage". scintigraphy is repeated at 6 month and echocardiography is also repeated at 1 month and 6 months. the primary endpoint is "salvage". accordingly, the aim is to demonstrate that salvage can be achieved with primary angioplasty for acute myocardial infarction despite symptom duration above 12 hours. clinical endpoints are death and reinfarction. the results are compared with results in 200 patients with symptom duration below 12 hours. these patients are treated and examined according to the exact same protocol. by this comparison, it can be evaluated whether it is relevant that the current guidelines recommend acute balloon angioplasty only to patients with less than 12 hours of symptom duration.

Eligibility criteria:
inclusion criteria: * acute myocardial infarction with st-segment elevation; * symptom duration 12 hours to 72 hours. exclusion criteria: * age below 18 years; * bleeding disorders or anaemia or low levels of thrombocytes; * thrombolysis used during the present admission; * expected survival less than 1 year due to other diseases; * previous acute myocardial infarction or coronary by-pass surgery; * major operation within last 30 days; * heamorrhaghic stroke within last 3 months.

Keywords: acute myocardial infarction symptom duration primary angioplasty infarct size myocardial scintigraphy
calcinosis reduction by pyrophosphate in ssc

Conditions: Systemic Sclerosis; Scleroderma

Summary: calcinosis, i.e. crystal-like nodules are troublesome complication of systemic sclerosis, an autoimmune disease. pyrophosphate inhibits its formation is laborytory. we would like to test if orally administered pyrophosphate prevents calcinosis formation.

calcinosis, the formation of hydroxyapatite subcutaneous nodules, often complicates systemic sclerosis. there is no standard treatment for it. based upon our preclinical experienc, we would like to test it orally administered pyrophosphate inhibits calciosis.

Eligibility criteria:
inclusion criteria: * to meet acr/ eular classification criteria exclusion criteria: * severe upper minfestation of ssc * hypo- or hyperthyreoidism * qt prolongation on ecg

Keywords: calcinosis pyrophosphate
analysis of immediate urinary continence predictors after rs-rarp

Conditions: Prostate Cancer (Post Prostatectomy); Urinary Continence; Retzius-sparing Robot-assisted Radical Prostatectomy

Summary: this study is a retrospective, single-center clinical trial. it aims to retrospectively analyze the immediate postoperative urinary continence recovery in prostate cancer patients who underwent retzius-sparing robot-assisted radical prostatectomy in the investigators' center. based on the general conditions of patients, relevant perioperative clinical indicators, and parameters related to the sphincter and prostate gland measured by mri, it explores the influencing factors of immediate urinary continence recovery after retzius-sparing robot-assisted radical prostatectomy in prostate cancer patients and constructs a relevant prediction model, thereby providing clinical guidance value for predicting immediate postoperative urinary continence recovery.


Eligibility criteria:
inclusion criteria: * prostate cancer diagnosed by prostate biopsy and underwent retzius-sparing robot-assisted radical prostatectomy in the investigators' hospital. * received plain and contrast-enhanced pelvic or prostate mri examinations before surgery. * eastern cooperative oncology group (ecog) performance status score between 0 and 1. * complete clinicopathological data. * in good general condition, without infections, autoimmune diseases, hematological diseases or other malignant tumors. * complete postoperative follow-up data, with a postoperative follow-up time of no less than 6 months. exclusion criteria: * the patient has surgical contraindications. * the patient has contraindications for mri examination. * preoperative presence of congenital urinary system malformations, urinary incontinence or severe lower urinary tract symptoms, and with a history of urinary catheter or previous transurethral resection of the prostate (turp) surgery. * having received neoadjuvant treatments that may affect the results of this study, such as radiotherapy or hormonal therapy. * the patient has other concurrent malignant tumors. * the patient has delayed extubation (\> 14 days). * the patient's clinical, imaging and pathological data are incomplete or the patient is lost to follow-up.

Keywords: retzius-sparing robot-assisted radical prostatectomy prostate cancer urinary continence